Karyopharm Therapeutics Inc.·4

Mar 3, 4:29 PM ET

Abate Kristin 4

4 · Karyopharm Therapeutics Inc. · Filed Mar 3, 2026

Insider Transaction Report

Form 4
Period: 2026-03-02
Abate Kristin
Chief Accounting Officer
Transactions
  • Sale

    Common Stock

    [F1]
    2026-03-02$9.41/sh559$5,26022,063 total
Footnotes (1)
  • [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Signature
/s/ Nancy Smith as Attorney-in-Fact for Kristin Abate|2026-03-03

Documents

1 file
  • 4
    ownership.xmlPrimary

    4